PT - JOURNAL ARTICLE AU - Wei, Wenjing AU - Ortwine, Jessica K. AU - Mang, Norman S. AU - Joseph, Christopher AU - Hall, Brenton C. AU - Prokesch, Bonnie C. TI - Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection AID - 10.1101/2020.06.16.20133181 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.16.20133181 4099 - http://medrxiv.org/content/early/2020/06/18/2020.06.16.20133181.short 4100 - http://medrxiv.org/content/early/2020/06/18/2020.06.16.20133181.full AB - Background There is currently a paucity of data describing bacterial coinfections, related antibiotic prescribing patterns, and the potential role of antimicrobial stewardship in the care of patients infected with SARS-CoV-2.Methods This prospective, observational study was conducted from March 10, 2020 to April 21, 2020 in admitted patients with confirmed COVID-19. Patients were included if ≥ 18 years old and admitted to the hospital for further treatment. Data was collected via chart review from the enterprise electronic health record database. Data collected include factors driving antibiotic choice, indication, and duration of therapy as well as microbiological data.Findings Antibiotics were initiated on admission in 87/147 (59%) patients. Of these, 85/87 (98%) prescriptions were empiric. The most common indication for empiric antibiotics was concern for community-acquired pneumonia (76/85, 89%) with the most prescribed antibiotics being ceftriaxone and azithromycin. The median duration of antibiotic therapy was two days (interquartile range 1-5). No patients had a community-acquired bacterial respiratory coinfection, but 10/147 (7%) of patients were found to have concurrent bacterial infections from a non-respiratory source, and one patient was diagnosed with active pulmonary tuberculosis at the time of admission for COVID-19.Interpretation Bacterial coinfection in patients with COVID-19 was infrequent. Antibiotics are likely unnecessary in patients with mild symptoms. There is little role for broad-spectrum antibiotics to empirically treat multidrug resistant organisms in patients with COVID-19, regardless of disease severity. Antimicrobial stewardship remains important in patients infected with SARS-CoV-2.Funding The authors received no funding for this work.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no external funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the IRB at the University of Texas Southwestern Medical Center and site approval was given by Parkland Health and Hospital System.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is contained within the manuscript or supplements submitted.